November 11 earnings are next for Cue Biopharma stock
Published on 10/15/2026 at 19:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEarnings date and valuation
- Cue Biopharma is listed for an earnings report on November 11, 2026.
- Revenue reached USD 7.88 million in the second quarter of 2026.
- Cue Biopharma stock costs EUR 16.07 at Lang & Schwarz on October 15, 2026 at 7:15 p.m. CEST, down 2.10 percent on Nasdaq.
- The company had a market capitalization of USD 132.3 million on October 15, 2026.
A November 11, 2026 earnings date is listed for Cue Biopharma by Market Chameleon. The date gives investors the next scheduled checkpoint after the companys second-quarter report. Cue Biopharma stock was trading at EUR 16.07 at Lang & Schwarz on October 15, 2026 at 7:15 p.m. CEST.
Second-quarter revenue reached USD 7.88 million
Cue Biopharma reported USD 7.88 million in revenue for the second quarter of 2026, compared with analyst estimates of USD 3.00 million, according to MarketBeat. The same report put adjusted earnings per share at a loss of USD 24.14, versus a consensus loss of USD 1.69. The revenue comparison was positive, while the earnings figure pointed to a wide gap between reported performance and expectations.
Price position and trading range
On Nasdaq, CUE was at USD 18.21 on October 15, 2026 at 1:23 p.m. ET, down 2.10 percent from the prior close. The stock traded within a USD 4.97 to USD 45.50 52-week range on October 15, 2026. Its market capitalization was USD 132.3 million, while average volume stood at 272,095 shares.
Valuation and upcoming date
Cue Biopharma had a negative price-to-earnings ratio of 0.66 on October 15, 2026 and paid no trailing dividend. The November 11, 2026 earnings date is described as projected, so the report remains the next dated event currently cited for the company.
Comparison with peers
Cue Biopharma (Nasdaq, USD): down 2.10 percent, P/E minus 0.66, market capitalization USD 132.3 million
Immunocore Holdings (Nasdaq, USD): up 3.56 percent, P/E minus 154.23, market capitalization USD 1.5 billion
Immunic (Nasdaq, USD): up 4.35 percent, P/E minus 1.45, market capitalization USD 94.8 million
What the next report will show
The November report will put the companys clinical pipeline and cash position back on the calendar. Cue Biopharma describes CUE-221 as moving toward a Phase 2b/3 study in chronic spontaneous urticaria and a planned Phase 2 study in food allergy, while CUE-401 is advancing toward Phase 1, according to the companys investor-relations profile.
Price remains the market frame
The euro quotation was EUR 16.07 at Lang & Schwarz on October 15, 2026 at 7:15 p.m. CEST. Nasdaq data placed the US listing at USD 18.21 at 1:23 p.m. ET on the same date, down 2.10 percent from its prior close.
The further course of trading is shown by the continuously updated real-time quote of Cue Biopharma stock.
Cue Biopharma market facts
- Company: Cue Biopharma, Inc.
- ISIN: US22978P2056
- Ticker: CUE
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 7:15 p.m. CEST): EUR 16.07
- Nasdaq daily change: minus 2.10 percent on October 15, 2026
- Market capitalization: USD 132.3 million (as of October 15, 2026)
- 52-week range: USD 4.97-45.50 (as of October 15, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 11, 2026
Market context: Market report Nasdaq Composite.
